Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: A case-controlled study

International Journal of Surgery

Volumn 6, Issue 3, 2008, Pages 205-209

  Sartore, Leonardo ^a   Papanikolaou, Georgios E ^a   Biancari, Fausto ^b   Mazzoleni, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cutaneous melanoma; Metastasis; Prognostic factors; Sentinel lymph node biopsy

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SKIN ULCER;

EID: 44949251702     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2008.03.003     Document Type: Article

References (25)

1. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
2. Paek S.C., Griffith K.A., Johnson T.M., Sondak V.K., Wong S.L., Chang A.E., et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109 (2007) 100-108
3. Balch C.M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 6 (1988) 163-172
4. Morton D.L., Wen D.R., and Cochran A.J. Management of early stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1 (1992) 247-259
5. Drepper H., Kohler C.O., Bastian B., Breuninger H., Brocker E.B., Gohl J., et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer 72 (1993) 741-749
6. Cascinelli N., Morabito A., Santinami M., MacKie R.M., and Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. WHO Melanoma Programme. Lancet 351 (1998) 793-796
7. Sim F.H., Taylor W.F., Pritchard D.J., and Soule E.H. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 61 (1986) 697-705
8. Morton D.L., Wen D.R., Wong J.H., Economou J.S., Cagle L.A., Storm F.K., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
9. Alex J.C., Weaver D.L., Fairbank J.T., Rankin B.S., and Krag D.N. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2 (1993) 303-308
10. Thompson J.F., McCarthy W.H., Bosch C.M., O'Brien C.J., Quinn M.J., Paramaesvaran S., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5 (1995) 255-260
11. Berk D.R., Johnson D.L., Uzieblo A., Kiernan M., and Swetter S.M. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol 141 (2005) 1016-1022
12. Vuylsteke R.J., van Leeuwen P.A., Statius Muller M.G., Gietema H.A., Kragt D.R., and Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 21 (2003) 1057-1065
13. Morton D.L., Cochran A.J., Thompson J.F., Elashoff R., Essner R., Glass E.C., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242 (2005) 302-311 [discussion 311-3]
14. Morton D.L., Thompson J.F., Essner R., Elashoff R., Stern S.L., Nieweg O.E., et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230 (1999) 453-463 [discussion 463-5]
15. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Elashoff R., Essner R., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006) 1307-1317
16. Nowecki Z.I., Rutkowski P., Nasierowska-Guttmejer A., and Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes-one institution's experience. Melanoma Res 13 (2003) 35-43
17. Nguyen C.L., McClay E.F., Cole D.J., O'Brien P.H., Gillanders W.E., Metcalf J.S., et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 181 (2001) 8-11
18. McMasters K.M., Wong S.L., Edwards M.J., Ross M.I., Chao C., Noyes R.D., et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130 (2001) 151-156
19. Wagner J.D., Corbett L., Park H.M., Davidson D., Coleman J.J., Havlik R.J., et al. Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures. Plast Reconstr Surg 105 (2000) 1956-1966
20. Zettersten E., Sagebiel R.W., Miller III J.R., Tallapureddy S., Leong S.P., and Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 94 (2002) 1049-1056
21. Azzola M.F., Shaw H.M., Thompson J.F., Soong S.J., Scolyer R.A., Watson G.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97 (2003) 1488-1498
22. Ranieri J.M., Wagner J.D., Wenck S., Johnson C.S., and Coleman III J.J. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 13 (2006) 927-932
23. Rex J., Paradelo C., Mangas C., Hilari J.M., Fernandez-Figueras M.T., Fraile M., et al. Singe-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg 31 (2005) 1385-1393
24. Statius Muller M.G., van Leeuwen P.A., van Diest P.J., Vuylsteke R.J., Pijpers R., Meijer S., et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 11 (2001) 303-307
25. Puleo C.A., Messina J.L., Riker A.I., Glass L.F., Nelson C., Cruse C.W., et al. Sentinel node biopsy for thin melanomas: which patients should be considered?. Cancer Control 12 (2005) 230-235